Chemotherapy Immunization Presentation 
pharmaphorum
MAY 30, 2022
pharmaphorum sat down with Sunil Verma, global head of oncology, medical, at AstraZeneca, to discuss three studies that were presented at the show, which demonstrate a few of the ways oncology is advancing through precision medicine and targeted therapies. And once it’s present there, it’s taken up by the cancer cell.
European Pharmaceutical Review
JUNE 5, 2023
Ninety-four percent of advanced stage (3 or 4) classic Hodgkin lymphoma patients treated with nivolumab, a PD-1 checkpoint inhibitor plus AVD chemotherapy (N-AVD) had one-year progression-free survival (PFS), according to Phase III trial results. Then 487 were part of the BV-AVD group.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
OCTOBER 25, 2024
The biologic ZL-1310 is being investigated in an ongoing Phase Ia/Ib study in these patients who have had at least one platinum-based chemotherapy regimen. This initial data on ZL-1310 was presented this week at the EORTC-NCI-AACR (ENA) Symposium 2024.
pharmaphorum
JANUARY 26, 2023
More specifically, CAR-T cell therapy engineers a patient’s own immune cells (T-cells) to detect, target, and destroy cancer cells. After initial chemotherapy, up to 45% of patients with DLBCL will require a second line treatment, which often involves high-dose chemotherapy and a stem cell transplant.
European Pharmaceutical Review
MAY 12, 2023
High-magnitude vaccine-induced T cell responses, the focus of the immune response analysis that included a new method to track vaccine-expanded clones, correlated with delayed PDAC recurrence. The personalised neoantigen vaccine was based on uridine mRNA–lipoplex nanoparticles. Rojas et al.
European Pharmaceutical Review
MAY 4, 2023
Amivantamab was the first bispecific monoclonal antibody (BsMAb) approved in the EU to treat advanced NSCLC with EGFR exon 20 insertion mutations post chemotherapy. Overall, the mechanisms of action for amivantamab include ligand blocking, receptor degradation, and immune cell-mediated activity. Oral Presentation JGN-75414.
pharmaphorum
NOVEMBER 29, 2022
Amplifying and reinvigorating persistent T cell immunity has become a much-needed path to enhance anti-tumor efficacy. T cells are known to mediate anti-tumor immune responses. For that reason, they have become the key target of immune checkpoint therapies, like PD-(L)1 agents.
Expert insights. Personalized for you.
116 
Let's personalize your content